Committee debates OGB weight-management plan that would give employees access to manufacturer platforms

Sponsor presented SB250 as a way to give OGB enrollees access to a comprehensive weight-management plan and to notify employees about direct-purchase options for FDA-approved GLP‑1 medications, with enrollees covering 100% of plan premiums per the sponsor’s amendments.

"The amendments require OGB to offer enrollment in a comprehensive weight management plan beginning 01/01/2027 and requires the enrollee to cover 100% of the cost of the premium for the plan," the sponsor said. Heath Williams of the Office of Group Benefits told the committee OGB covers about 211,000 members and estimated roughly 76,000 would potentially be eligible for the proposed plan.

Bill Reed, vice president for state government affairs at Eli Lilly, described the Lilly Direct platform as a digital pathway offering telehealth and direct-to-pharmacy services and said manufacturers can help negotiate price by offering access to larger enrollment pools. "Lilly Direct is our digital health care platform... Our goal is to relieve some of the complexity in the U.S. healthcare system," Reed said.

Physicians who treat obesity urged broader access but questioned placing the full cost burden on employees. Dr. Catherine Hudson, an obesity-medicine physician, testified that manufacturer direct-to-consumer channels already can yield discounted prices and that further manufacturer concessions for OGB members would be welcome. Dr. Katie Queen, representing the Louisiana Obesity Society, said she supports access but prefers a cost-sharing arrangement between OGB and patients to avoid placing the entire expense on employees.

Committee members pressed for administrative and fiscal clarity, including who would administer the plan and what administrative fees would be required. An amendment (22‑85) was adopted to clarify language and posture; senators requested further modeling on fiscal and administrative impact before advancing further.

The committee did not record a final committee vote on passage; sponsors said they would continue to work with stakeholders to clarify administration and pricing mechanisms.